| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Histamine H2 receptor (HRH2) - indirect via parent compound. Ranitidine-S-oxide itself has significantly reduced H2 receptor antagonist activity compared to the parent drug. Its primary relevance is as a metabolite, with its formation representing a major clearance pathway for ranitidine. The compound may retain some degree of H2 receptor affinity but is pharmacologically much weaker than ranitidine.
|
|---|---|
| ln Vitro |
In vitro, Ranitidine-S-oxide is characterized primarily as a metabolite rather than an active pharmacological agent. It demonstrates acutely cytotoxic effects, though the clinical significance of this finding is unclear. The compound is used in analytical assays to study ranitidine metabolism and to assess the activity of FMO enzymes. Its formation in hepatic microsomal preparations serves as a marker for FMO-mediated metabolism.
|
| ln Vivo |
In vivo, Ranitidine-S-oxide is formed following oral administration of ranitidine and is excreted in urine. As the major metabolite, it contributes to the overall pharmacokinetic profile of the parent drug. Its formation is dependent on FMO3 and FMO5 activity, which can be influenced by genetic polymorphisms and drug interactions. The metabolite does not contribute significantly to the therapeutic effects of ranitidine due to its reduced pharmacological activity.
|
| Enzyme Assay |
Cell-free enzyme assays for Ranitidine-S-oxide formation typically use human liver microsomes or recombinant FMO3 and FMO5 enzymes. The reaction mixture contains ranitidine, NADPH (for FMO activity), and the enzyme preparation, incubated at 37°C for 30-60 minutes. The formation of Ranitidine-S-oxide is quantified by HPLC or LC-MS/MS. Enzyme kinetics (Km, Vmax) are determined by varying substrate concentrations. Inhibitor studies can be performed using selective FMO inhibitors to confirm the enzyme responsible for metabolite formation.
|
| Cell Assay |
Cellular assays for Ranitidine-S-oxide are limited, as the compound is primarily a metabolite standard. When used in cell-based systems, it may be tested for cytotoxicity using hepatocyte cell lines (e.g., HepG2) to assess metabolite-related toxicity. Cells are seeded in multiwell plates, treated with varying concentrations of Ranitidine-S-oxide for 24-72 hours, and cell viability is measured using MTT or LDH release assays. Results are compared to the parent compound to determine if the metabolite contributes to ranitidine's safety profile.
|
| Animal Protocol |
In vivo animal studies involving Ranitidine-S-oxide are typically pharmacokinetic studies where ranitidine is administered to rodents or other preclinical species, and the formation of Ranitidine-S-oxide is monitored in plasma and urine. Blood and urine samples are collected at various time points and analyzed by LC-MS/MS. The metabolite's exposure (AUC, Cmax) is correlated with ranitidine dosing. Studies may also investigate the effect of FMO inhibition or induction on the formation of Ranitidine-S-oxide to understand metabolic clearance pathways.
|
| ADME/Pharmacokinetics |
As a metabolite of ranitidine, Ranitidine-S-oxide is formed systemically and excreted primarily via renal clearance. Its pharmacokinetic profile mirrors that of the parent drug, with formation being the rate-limiting step for its appearance in the circulation. The compound's half-life is determined by the elimination of the metabolite, which is primarily through urinary excretion. Its plasma protein binding is likely similar to that of ranitidine. The metabolite does not accumulate significantly with repeated dosing due to efficient renal clearance.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ranitidine-S-oxide indicate that it is acutely cytotoxic. However, the clinical relevance of this finding is uncertain, as the metabolite is formed systemically and is normally excreted without accumulation. Standard toxicology studies of ranitidine have evaluated the safety of the parent drug, with the metabolite considered part of the overall safety profile. No specific toxicological syndromes have been attributed to Ranitidine-S-oxide in clinical use.
|
| Additional Infomation |
Ranitidine-S-oxide is a sulfoxide derivative of the drug ranitidine. It is both a marine xenobiotic metabolite and a drug metabolite. It belongs to the furan class, tertiary amine class, C-nitro class, and sulfoxide class.
Ranitidine-S-oxide is a metabolite reference standard used in drug metabolism and pharmacokinetics research. It is not a therapeutic agent and has no clinical indications. The compound is available from chemical suppliers for research purposes only. It is typically stored at -20°C and handled according to standard laboratory safety protocols. Its role as a major metabolite makes it valuable for studying ranitidine disposition and for developing analytical methods for drug monitoring. |
| Molecular Formula |
C13H22N4O4S
|
|---|---|
| Molecular Weight |
330.40
|
| Exact Mass |
330.136
|
| CAS # |
73851-70-4
|
| PubChem CID |
3033889
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.265g/cm3
|
| Boiling Point |
527.5ºC at 760 mmHg
|
| Flash Point |
272.8ºC
|
| Index of Refraction |
1.577
|
| LogP |
2.645
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
22
|
| Complexity |
411
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N/C(N(CCS(CC1=CC=C(CN(C)C)O1)=O)C)=C\[N+]([O-])=O
|
| InChi Key |
SKHXRNHSZTXSLP-UKTHLTGXSA-N
|
| InChi Code |
InChI=1S/C13H22N4O4S/c1-14-13(9-17(18)19)15-6-7-22(20)10-12-5-4-11(21-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
|
| Chemical Name |
(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfinyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~378.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0266 mL | 15.1332 mL | 30.2663 mL | |
| 5 mM | 0.6053 mL | 3.0266 mL | 6.0533 mL | |
| 10 mM | 0.3027 mL | 1.5133 mL | 3.0266 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
